Page 8 - Graphite Bio News Today

Gene therapy clinical trial pipeline constitutes 250+ key companies continuously working towards developing 300+ gene therapies, analyzes DelveInsight LAS VEGAS, Nov. 2, 2022 /PRNewswire/

/PRNewswire/ -- DelveInsights Gene Therapy Competitive Landscape – 2022 report provides comprehensive global coverage of available, marketed, and pipeline...

While worthy advances have recently been made in sickle cell disease, companies such as Graphite Bio, bluebird bio, Vertex Pharmaceuticals and Editas Medicine have loftier ambitions.  

Graphite Bio, Inc. (NASDAQ:GRPH) is a clinical-stage gene editing company based in San Francisco, California. It develops therapies for life-threatening diseases in the United States.

/PRNewswire/ -- The overall Fabry disease market is likely to surge owing to the increasing prevalence of the disease along with the promising emerging...

Vertex Redesign

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) – Equities researchers at Cantor Fitzgerald issued their FY2022 earnings estimates for Graphite Bio in a report issued on Thursday, September 15th. Cantor Fitzgerald analyst O. Brayer forecasts that the company will post earnings per share of ($1.45) for the year. Cantor Fitzgerald currently has a “Overweight” rating […]

/PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological...

Keynote by Admiral Rachel Levine, M.D., Assistant Secretary for Health, U.S. Department of Health and Human Services...

BioPharma